Tyligand Bioscience receives IND clearance from U.S. FDA for TSN084, a Multi-kinase Inhibitor to address tumor resistance to targeted therapies
Shanghai, Oct. 17th, 2021 – Tyligand Bioscience, a clinical-stage biotechnology company focused on developing innovative therapies against drug resistant cancers, announces that the U.S. Food and Drug Administration (FDA) has approved the Company’s Investigational New Drug (IND) application to commence a Phase I clinical trial investigating the safety and efficacy of TSN084 for treating solid tumors. TSN084 is a novel multi-kinase inhibitor targeting CDK8/19 and several other kinases implicated in tumorigenesis and immune evasions. The clinical study is scheduled to start at the M.D Anderson Cancer Center in the US soon.
Dr. Tony Zhang, cofounder and CEO of Tyligand Bioscience, commented:
“TSN084 is the front runner of the Tyligand pipeline of innovative molecules designed to treat tumors that become resistant to targeted therapies. It has demonstrated potent activities against a unique combination of kinase targets responsible for several major cancer hallmarks in preclinical studies. FDA’s decision has moved us one step closer towards translating these findings into clinical outcomes for patients suffering from NSCLC, TNBC and other hard to treat cancers.”
About Tyligand Bioscience (Shanghai) Limited
Tyligand Bioscience is a clinical stage biotechnology company focused on the discovery and development of cancer therapeutics to address drug resistant tumors like NSCLC and TNBC. Leveraging deep insights into the chemistry of biomolecule phosphorylation, the company has efficiently built a differentiated pipeline including 1st-in-class Dual Action Tumor Immune Agonist (DATIA®) assets and a novel platform for ADC payload discovery and development.